David Chung, MD
Family Medicine · Sparta, ILNPI 1417914557
Payments from drug & device makers
Across 103 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$356
- Davol Inc.$353
- Lilly USA, LLC$240
- AbbVie$195
- AstraZeneca$135
- Stryker$108
- plus $942 from 20 others
What the payments were for
- Travel & lodging$32314%
- Food & beverage$2,00786%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 3 | $356 |
| Davol Inc. | 2 | $353 |
| Lilly USA, LLC | 17 | $240 |
| AbbVie(2 entities) | 12 | $195 |
| AstraZeneca | 8 | $135 |
| Stryker | 1 | $108 |
| Novo Nordisk | 7 | $99 |
| Boehringer Ingelheim | 6 | $92 |
| Amgen | 5 | $87 |
| Novartis | 6 | $84 |
| GSK | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Amarin Pharma, Inc. | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 1 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Pfizer | 3 | $48 |
| Merck | 3 | $46 |
| Astellas Pharma US Inc | 3 | $42 |
| Biosense Webster, Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $20 |
| Vertex | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 2 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,330 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $139,186 |
| OzempicSemaglutide | 99 | $132,057 |
| MounjaroTirzepatide | 40 | $58,521 |
| LinzessLinaclotide | 87 | $54,127 |
| JanuviaSitagliptin Phosphate | 64 | $48,313 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $46,244 |
| JardianceEmpagliflozin | 31 | $36,956 |
| FarxigaDapagliflozin Propanediol | 48 | $34,162 |
| XareltoRivaroxaban | 42 | $31,391 |
| TrulicityDulaglutide | 26 | $27,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $19,608 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $18,441 |
| GemtesaVibegron | 47 | $18,101 |
| UbrelvyUbrogepant | 17 | $17,435 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $17,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $48 | $146,015218 claims |
| Novo NordiskOzempic | $99 | $132,05799 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $240 | $91,09177 claims |
| AbbVieLinzess, Ubrelvy | $195 | $71,563104 claims |
| MerckJanuvia, Belsomra | $46 | $56,86383 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $135 | $45,43266 claims |
| Boehringer IngelheimJardiance | $92 | $36,95631 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $74 | $34,23945 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13 | $18,10147 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $15,84532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Sparta
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.